© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to September
oral ROR_ nuclear receptor agonist
450 mg BID, phase I/II, cancer
from change in MoA of ROR_ antagonist + opt.
Journal of Medicinal Chemistry
The Lycera ROR gamma agonist, cintirorgon (LYC-55716), is a first-in-class phase 1b clinical candidate for cancer immunotherapy (in combination with pembrolizumab in NSCLC). ROR gamma antagonists have been extensively…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.